Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Common Equity (2016 - 2026)

Akebia Therapeutics has reported Common Equity over the past 11 years, most recently at $32.6 million for Q4 2025.

  • Quarterly Common Equity rose 166.3% to $32.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.6 million through Dec 2025, up 166.3% year-over-year, with the annual reading at $32.6 million for FY2025, 166.3% up from the prior year.
  • Common Equity was $32.6 million for Q4 2025 at Akebia Therapeutics, down from $41.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $213.9 million in Q1 2021 and troughed at -$50.4 million in Q3 2024.
  • The 5-year median for Common Equity is $15.4 million (2022), against an average of $27.3 million.
  • Year-over-year, Common Equity plummeted 684.78% in 2023 and then skyrocketed 190.18% in 2025.
  • A 5-year view of Common Equity shows it stood at $74.0 million in 2021, then crashed by 92.93% to $5.2 million in 2022, then plummeted by 684.78% to -$30.6 million in 2023, then tumbled by 60.82% to -$49.2 million in 2024, then skyrocketed by 166.3% to $32.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Common Equity are $32.6 million (Q4 2025), $41.6 million (Q3 2025), and $29.2 million (Q2 2025).